Some cancer therapies try to block a tumour’s growth signal. Others try to make the tumour easier for the immune system to see. Australian biotechnology company ImmVirX is developing a virus-based approach that aims to do both direct damage and immune activation.
In an update dated 28 September 2026 and posted on 29 September, the company outlined a planned Phase II IMPACT-CRC study of IVX037 with PD-1 inhibition in a genetically defined group of colorectal cancers. The programme is a development plan, and the company explicitly says it is subject to further financing. ImmVirX’s annual operations update
Featured image: National Cancer Institute / Unsplash. Representative photograph; it does not depict the specific study, product or facility described.
PD-1 inhibition aims to release an immune-system brake, helping immune cells attack cancer. “Microsatellite-stable” means the tumour does not show the instability in short repeated DNA sequences used to identify a different molecular subgroup. NCI explanation of immune checkpoints and colorectal cancer genetics
A virus directed at cancer cells
“Oncolytic” means cancer-cell destroying. ImmVirX’s platform uses RNA viruses selected to enter cells through receptor proteins that are abundant on particular cancers. The intended effect combines tumour-cell destruction with an immune response against the cancer. IVX037 is being tested in people; that does not establish clinical benefit. Platform and clinical-stage description
The planned study focuses on KRAS- or BRAF-mutant, microsatellite-stable colorectal cancer. KRAS and BRAF are genes involved in growth-signalling pathways. Microsatellite-stable describes a molecular classification of the tumour. Defining this population matters because a response in one cancer subtype cannot automatically be extended to every bowel cancer. Planned study population
Early signals, with important gaps
The company says its Phase Ia study supported repeated injection into tumours, and that Phase Ib combination work produced preliminary support for further evaluation in colorectal and ovarian cancer. The annual update does not provide a full controlled efficacy analysis or quantified survival benefit. Phase I progress
Phase I work primarily builds the foundation for dose, safety and feasibility. Larger studies can then ask whether treatment improves meaningful outcomes in a defined population. Combining therapies also creates an attribution problem: investigators need a design that can show what the added virus contributes.
A manufacturing plan is part of the science
ImmVirX reports that manufacturing to clinical quality standards is established through a US contractor. Reliable supply matters when a programme moves from a small study to several hospitals, but manufacturing readiness and therapeutic effectiveness are separate milestones. Manufacturing update
The next useful evidence will be a final trial design, financing and recruitment progress, followed by sufficiently detailed clinical results. The update shows a sharper research direction for an Australian platform, while the hardest question—whether it delivers durable benefit—remains ahead.
Leave a Reply